vs
Side-by-side financial comparison of PARK NATIONAL CORP (PRK) and Vericel Corp (VCEL). Click either name above to swap in a different company.
PARK NATIONAL CORP is the larger business by last-quarter revenue ($168.3M vs $92.9M, roughly 1.8× Vericel Corp). PARK NATIONAL CORP runs the higher net margin — 25.3% vs 25.0%, a 0.3% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 2.2%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 4.9%).
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
PRK vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.3M | $92.9M |
| Net Profit | $42.6M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 25.3% | 25.0% |
| Revenue YoY | 2.2% | 23.3% |
| Net Profit YoY | 10.4% | 17.3% |
| EPS (diluted) | $2.62 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.3M | $92.9M | ||
| Q3 25 | $169.5M | $67.5M | ||
| Q2 25 | $168.7M | $63.2M | ||
| Q1 25 | $157.9M | $52.6M | ||
| Q4 24 | $164.7M | $75.4M | ||
| Q3 24 | $170.3M | $57.9M | ||
| Q2 24 | $157.7M | $52.7M | ||
| Q1 24 | $152.8M | $51.3M |
| Q4 25 | $42.6M | $23.2M | ||
| Q3 25 | $47.2M | $5.1M | ||
| Q2 25 | $48.1M | $-553.0K | ||
| Q1 25 | $42.2M | $-11.2M | ||
| Q4 24 | $38.6M | $19.8M | ||
| Q3 24 | $38.2M | $-901.0K | ||
| Q2 24 | $39.4M | $-4.7M | ||
| Q1 24 | $35.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 34.3% | 5.1% | ||
| Q2 25 | 35.2% | -3.2% | ||
| Q1 25 | 32.4% | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 27.4% | -4.3% | ||
| Q2 24 | 30.6% | -11.5% | ||
| Q1 24 | 27.8% | -10.7% |
| Q4 25 | 25.3% | 25.0% | ||
| Q3 25 | 27.8% | 7.5% | ||
| Q2 25 | 28.5% | -0.9% | ||
| Q1 25 | 26.7% | -21.4% | ||
| Q4 24 | 23.5% | 26.3% | ||
| Q3 24 | 22.4% | -1.6% | ||
| Q2 24 | 25.0% | -8.9% | ||
| Q1 24 | 23.0% | -7.5% |
| Q4 25 | $2.62 | $0.46 | ||
| Q3 25 | $2.92 | $0.10 | ||
| Q2 25 | $2.97 | $-0.01 | ||
| Q1 25 | $2.60 | $-0.23 | ||
| Q4 24 | $2.38 | $0.40 | ||
| Q3 24 | $2.35 | $-0.02 | ||
| Q2 24 | $2.42 | $-0.10 | ||
| Q1 24 | $2.17 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $354.6M |
| Total Assets | $9.8B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $233.5M | $137.5M | ||
| Q3 25 | $218.9M | $135.4M | ||
| Q2 25 | $193.1M | $116.9M | ||
| Q1 25 | $237.6M | $112.9M | ||
| Q4 24 | $160.6M | $116.2M | ||
| Q3 24 | $201.7M | $101.7M | ||
| Q2 24 | $261.5M | $102.5M | ||
| Q1 24 | $306.1M | $110.6M |
| Q4 25 | $1.4B | $354.6M | ||
| Q3 25 | $1.3B | $321.9M | ||
| Q2 25 | $1.3B | $306.8M | ||
| Q1 25 | $1.3B | $295.5M | ||
| Q4 24 | $1.2B | $292.0M | ||
| Q3 24 | $1.2B | $257.5M | ||
| Q2 24 | $1.2B | $243.0M | ||
| Q1 24 | $1.2B | $233.9M |
| Q4 25 | $9.8B | $488.0M | ||
| Q3 25 | $9.9B | $453.3M | ||
| Q2 25 | $9.9B | $435.6M | ||
| Q1 25 | $9.9B | $424.6M | ||
| Q4 24 | $9.8B | $432.7M | ||
| Q3 24 | $9.9B | $390.4M | ||
| Q2 24 | $9.9B | $376.8M | ||
| Q1 24 | $9.9B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $198.3M | $15.0M |
| Free Cash FlowOCF − Capex | $191.9M | $12.8M |
| FCF MarginFCF / Revenue | 114.1% | 13.8% |
| Capex IntensityCapex / Revenue | 3.8% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.65× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $328.2M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.3M | $15.0M | ||
| Q3 25 | $52.6M | $22.1M | ||
| Q2 25 | $49.7M | $8.2M | ||
| Q1 25 | $37.9M | $6.6M | ||
| Q4 24 | $178.8M | $22.2M | ||
| Q3 24 | $43.8M | $10.2M | ||
| Q2 24 | $50.9M | $18.5M | ||
| Q1 24 | $35.0M | $7.2M |
| Q4 25 | $191.9M | $12.8M | ||
| Q3 25 | $51.1M | $19.5M | ||
| Q2 25 | $48.4M | $81.0K | ||
| Q1 25 | $36.8M | $-7.6M | ||
| Q4 24 | $169.7M | $8.5M | ||
| Q3 24 | $41.7M | $-9.2M | ||
| Q2 24 | $49.0M | $1.8M | ||
| Q1 24 | $31.9M | $-6.8M |
| Q4 25 | 114.1% | 13.8% | ||
| Q3 25 | 30.1% | 28.8% | ||
| Q2 25 | 28.7% | 0.1% | ||
| Q1 25 | 23.3% | -14.5% | ||
| Q4 24 | 103.0% | 11.2% | ||
| Q3 24 | 24.5% | -15.9% | ||
| Q2 24 | 31.1% | 3.4% | ||
| Q1 24 | 20.8% | -13.3% |
| Q4 25 | 3.8% | 2.4% | ||
| Q3 25 | 0.9% | 3.9% | ||
| Q2 25 | 0.8% | 12.9% | ||
| Q1 25 | 0.7% | 27.0% | ||
| Q4 24 | 5.6% | 18.3% | ||
| Q3 24 | 1.2% | 33.5% | ||
| Q2 24 | 1.2% | 31.8% | ||
| Q1 24 | 2.1% | 27.3% |
| Q4 25 | 4.65× | 0.65× | ||
| Q3 25 | 1.11× | 4.35× | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 4.63× | 1.12× | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 0.99× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRK
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
